Abstract | OBJECTIVE: METHODS: This study enrolled 116 patients who had histologically or cytologically confirmed adenocarcinoma and been diagnosed as relapsing after resection or with unresectable intrahepatic cholangiocarcinoma. We evaluated the frequency of fibroblast growth factor receptor 2 fusions-positive cells in their specimens using break-apart fluorescent in situ hybridization 'for 114 patients who met the study protocol'. RESULTS: CONCLUSIONS:
|
Authors | Masanori Tsujie, Tomohisa Iwai, Shoji Kubo, Takashi Ura, Etsuro Hatano, Daisuke Sakai, Yutaka Takeda, Masaki Kaibori, Tomoe Kobayashi, Akio Katanuma, Yu Katayose, Koji Fukase |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 51
Issue 6
Pg. 911-917
(May 28 2021)
ISSN: 1465-3621 [Electronic] England |
PMID | 33822966
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Copyright | © The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Oncogene Proteins, Fusion
- FGFR2 protein, human
- Receptor, Fibroblast Growth Factor, Type 2
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Bile Duct Neoplasms
(epidemiology, genetics, metabolism, pathology)
- Bile Ducts, Intrahepatic
(metabolism, pathology)
- Cholangiocarcinoma
(genetics, metabolism, mortality, pathology)
- Female
- Gene Frequency
- Genetic Association Studies
- Genetic Predisposition to Disease
- Humans
- In Situ Hybridization, Fluorescence
- Japan
(epidemiology)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(pathology)
- Oncogene Proteins, Fusion
(genetics)
- Receptor, Fibroblast Growth Factor, Type 2
(genetics)
|